Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Osteosarcoma in Korean children and adolescents

  • Lee, Jun Ah (Department of Pediatrics, Korea Cancer Center Hospital)
  • Received : 2015.01.02
  • Accepted : 2015.03.03
  • Published : 2015.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Osteosarcoma is the most frequent primary bone tumor. Advances in combination chemotherapy and surgical technique have greatly improved the survival of patients with osteosarcoma. In Korea, improvements in osteosarcoma treatment have been made over the past two decades. The 5-year event-free survival rate of Korean children and adolescents with localized disease is 64.6%, comparable to that of American or European patients. This article provides an overview of current therapies for osteosarcoma in Korea.

Keywords

References

  1. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009;152:239-62. https://doi.org/10.1007/978-1-4419-0284-9_12
  2. Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, et al. Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients. Klin Padiatr 1999;211:260-70. https://doi.org/10.1055/s-2007-1019701
  3. Ministry for Health, Welfare and Family Affairs. Annual report of cancer incidence (2011), cancer prevalence (2011) and survival (1993-2011) in Korea. Seoul: Ministry for Health, Welfare and Family Affairs, 2011.
  4. Lee JA, Park BK; for the Korean Society of Pediatric Hematology and Oncology. Osteosarcoma of children and adolescents: analysis from the Korean Society of Pediatric Hematology-Oncology (KSPHO). In: Proceedings of the 59th Annual Meeting of the Korean Pediatric Society; 2009 Oct 23-24; Seoul, Korea.
  5. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian- Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-9. https://doi.org/10.1023/A:1008391103132
  6. Ferrari S, Briccoli A, Mercuri M, Bertoni F, Picci P, Tienghi A, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21:710-5. https://doi.org/10.1200/JCO.2003.03.141
  7. Lee YJ, Lee HJ, Kim DH, Lim JS, Lee JH, Park KD, et al. Outcome after relapse in childhood and adolescent osteosarcoma: single institution experience in Korea. Korean J Pediatr 2008;51:78-83. https://doi.org/10.3345/kjp.2008.51.1.78
  8. Song BS, Seo J, Kim DH, Lim JS, Yoo JY, Lee JA. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer 2014;61:1376-81. https://doi.org/10.1002/pbc.25035
  9. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-12. https://doi.org/10.1200/JCO.2004.08.043
  10. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31. https://doi.org/10.1200/JCO.2002.11.050
  11. Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno- Neumann S, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119:706-11. https://doi.org/10.1002/ijc.21867
  12. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-63. https://doi.org/10.1200/JCO.2006.10.4117
  13. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-25. https://doi.org/10.1002/cncr.23586
  14. Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 2012;59:854-8. https://doi.org/10.1002/pbc.24101
  15. Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol 2012;42:427-31. https://doi.org/10.1093/jjco/hys030
  16. Mora J, Cruz CO, Parareda A, de Torres C. Treatment of relapsed/ refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009;31:723-9. https://doi.org/10.1097/MPH.0b013e3181b2598c
  17. McGovern SL, Mahajan A. Progress in radiotherapy for pediatric sarcomas. Curr Oncol Rep 2012;14:320-6. https://doi.org/10.1007/s11912-012-0235-y
  18. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer Treat Res 2009;152:147-64. https://doi.org/10.1007/978-1-4419-0284-9_7
  19. Oertel S, Blattmann C, Rieken S, Jensen A, Combs SE, Huber PE, et al. Radiotherapy in the treatment of primary osteosarcoma: a single center experience. Tumori 2010;96:582-8. https://doi.org/10.1177/030089161009600411
  20. DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005;61:492-8. https://doi.org/10.1016/j.ijrobp.2004.05.051
  21. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006;16:2-9. https://doi.org/10.1016/j.semradonc.2005.08.001
  22. Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 2008;15:38-46. https://doi.org/10.1177/107327480801500105
  23. Salama JK, Vokes EE. New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol 2013;31:1029-38. https://doi.org/10.1200/JCO.2012.44.5064
  24. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-96. https://doi.org/10.1200/JCO.20.1.189
  25. Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153- EDTMP and radium-223. Adv Exp Med Biol 2014;804:291-304. https://doi.org/10.1007/978-3-319-04843-7_16
  26. Lee JA, Song BS, Choi AR, Lim SW, Ahn JH, Seo JH, et al. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. In: Proceedings of the 63th Annual Meeting of the Korean Pediatric Society; 2013 Oct 18-19; Seoul, Korea.
  27. Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer 2004;42:320-4. https://doi.org/10.1002/pbc.10393
  28. Saleh RA, Graham-Pole J, Cassano W, Abbot F, Vander Griend R, Dickson N, et al. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer 1990;65:861-5. https://doi.org/10.1002/1097-0142(19900215)65:4<861::AID-CNCR2820650405>3.0.CO;2-H
  29. Rodriguez-Galindo C, Daw NC, Kaste SC, Meyer WH, Dome JS, Pappo AS, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-5. https://doi.org/10.1097/00043426-200205000-00006
  30. Srinivasan U, Reaman GH, Poplack DG, Glaubiger DL, LeVine AS. Phase II study of 5-azacytidine in sarcomas of bone. Am J Clin Oncol 1982;5:411-5. https://doi.org/10.1097/00000421-198208000-00011
  31. Pratt CB, Meyer WH, Howlett N, Douglass EC, Bowman LC, Poe D, et al. Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. Cancer 1994;74:2593-8. https://doi.org/10.1002/1097-0142(19941101)74:9<2593::AID-CNCR2820740930>3.0.CO;2-C
  32. Nitschke R, Pratt C, Harris M, Krischer J, Vietti TJ, Grier H, et al. Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group). Invest New Drugs 1992;10:93-6. https://doi.org/10.1007/BF00873123
  33. Pawinski A, Crowther D, Keizer HJ, Voute PA, Somers R, van Glabbeke M, et al. The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma. Eur J Cancer 1999;35:163-4. https://doi.org/10.1016/S0959-8049(98)00266-4
  34. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-35. https://doi.org/10.1002/cncr.11563
  35. Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 1998;4:357-60.
  36. Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol 2002;20:2150-6. https://doi.org/10.1200/JCO.2002.08.081
  37. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004;16:120-5. https://doi.org/10.1097/00001622-200403000-00006
  38. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009;115:5339-48. https://doi.org/10.1002/cncr.24566
  39. Meyers PA, Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol 2014;804:307-21. https://doi.org/10.1007/978-3-319-04843-7_17
  40. Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, et al. Insulin- like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One 2014;9:e106249. https://doi.org/10.1371/journal.pone.0106249
  41. Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res 2011;17:611-9. https://doi.org/10.1158/1078-0432.CCR-10-1731
  42. Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 2015;16:98-107. https://doi.org/10.1016/S1470-2045(14)71136-2

Cited by

  1. Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes vol.16, pp.5, 2015, https://doi.org/10.3892/ol.2018.9453
  2. Inositol polyphosphate‐4‐phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3‐kinase/protein kinase B pathway vol.119, pp.12, 2018, https://doi.org/10.1002/jcb.27311
  3. Osteosarcoma in Children: Not Only Chemotherapy vol.14, pp.9, 2021, https://doi.org/10.3390/ph14090923
  4. Osteosarcoma in Adolescents and Young Adults vol.10, pp.10, 2021, https://doi.org/10.3390/cells10102684